Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study on the Safety and Effects of Losmapimod for Patients with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)

Verified siteInvestigational
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on studying Facioscapulohumeral Muscular Dystrophy 1 (FSHD1), a genetic disorder that causes muscle weakness, particularly in the face, shoulders, and upper arms. The study is testing a treatment called Losmapimod, which is taken as a film-coated tablet. The purpose of the study is to evaluate the safety and tolerability of long-term use of Losmapimod in individuals with FSHD1.

Participants in the study will take Losmapimod orally and will be monitored over a period of time to assess how well they tolerate the medication and to observe any changes in their condition. The study will also look at specific markers in the body that might indicate how the disease is progressing or responding to the treatment. Some participants may receive a placebo, which is a tablet that looks like the medication but does not contain the active ingredient.

The study will involve regular visits to the clinic for check-ups, which may include tests like blood work, heart monitoring (ECG), and other assessments to ensure the safety of the participants. The trial aims to gather important information that could help in understanding the effects of Losmapimod on FSHD1 and potentially improve treatment options for those affected by this condition.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Participation begins after signing an informed consent form. This confirms understanding and agreement to the study's terms.

    Eligibility is confirmed through a genetic test for Facioscapulohumeral Muscular Dystrophy 1 (FSHD1). This involves assessing the size of the D4Z4 array on chromosome 4.

  2. Step 2

    Screening phase

    A screening phase ensures all criteria are met. This includes a genetic confirmation, which may use previous test results if verified.

    During this phase, a muscle biopsy and MRI are scheduled to confirm eligibility.

  3. Step 3

    Treatment phase

    The treatment involves taking Losmapimod tablets orally. The dosage and frequency are determined by the study protocol.

    Participants must adhere to the treatment plan, including scheduled visits and laboratory tests.

  4. Step 4

    Monitoring and assessments

    Regular assessments are conducted to monitor safety and tolerability. This includes checking for any adverse effects, conducting laboratory tests, and recording vital signs.

    Participants undergo whole-body MRI and muscle biopsies as part of the monitoring process.

  5. Step 5

    Completion of main study

    The main study concludes after the Week 60 visit. Participants must complete this phase to be eligible for the extension study.

    Completion involves final assessments and documentation of outcomes.

  6. Step 6

    Extension study

    Participants who complete the main study may enter an extension phase. This continues the evaluation of Losmapimod over a longer period.

    The extension study follows similar procedures for monitoring and assessments as the main study.

Who can join the trial?

10 criteria

  • Patients must be between 18 and 65 years old.
  • Patients must have completed the main study up to the Week 60 visit to join the extension.
  • Patients need to sign and date a form that shows they agree to participate in the study.
  • Patients must have a confirmed diagnosis of **Facioscapulohumeral Muscular Dystrophy 1 (FSHD1)**, which is a genetic condition. This confirmation can come from previous tests if properly documented. If a patient has a close family member with a confirmed diagnosis, they may also be eligible for the study.
  • Patients should be willing and able to attend scheduled visits, follow the treatment plan, and comply with study rules, including laboratory tests and other procedures.
  • Both men and women can participate. Women who can have children must use effective birth control during the study and for 90 days after the last dose. Men must also agree to use birth control during the same period.
  • Patients must have a **Clinical Severity Score** between 2 and 4 on a specific scale used to measure the severity of their condition. Patients who use a wheelchair or walker cannot join the study.
  • Patients must agree to complete two visits for muscle biopsies and all visits for whole-body MRI scans.
  • Patients should be able to complete certain physical tests and questionnaires at the screening visit.
  • Patients must have a muscle that is suitable for biopsy, as determined by a specialist.

Who cannot join the trial?

9 criteria

  • Patients who have a different type of muscular dystrophy other than Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) cannot participate.
  • Individuals who are not within the specified age range for the study are excluded. The age range is typically defined in the study details.
  • Participants who are not able to follow the study procedures or take the study medication as required will be excluded.
  • People with certain medical conditions that might interfere with the study or pose a risk to their health if they participate will not be allowed to join.
  • Individuals who are currently participating in another clinical trial or have recently participated in one may be excluded.
  • Pregnant or breastfeeding women are usually not allowed to participate in clinical trials to avoid any potential risks to the baby.
  • Patients who have a history of allergic reactions to the study medication or similar drugs will be excluded.
  • Individuals with severe mental health issues that might affect their ability to participate in the study will not be included.
  • People who have a history of substance abuse, which could interfere with the study results, may be excluded.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Losmapimod is a medication being studied for its potential to help people with Facioscapulohumeral Muscular Dystrophy 1 (FSHD1). This study aims to see if taking losmapimod over a long period is safe and if it is well-tolerated by patients. Researchers are also looking at how it might affect certain biomarkers and clinical outcomes related to the disease.

What is already known about the treatment

Losmapimod – Losmapimod is administered orally in tablet form. It is currently being studied in clinical trials for its safety and tolerability in treating Facioscapulohumeral Muscular Dystrophy 1 (FSHD1). The main therapeutic indication for losmapimod is to manage symptoms associated with FSHD1. At the molecular level, losmapimod works by inhibiting certain enzymes involved in inflammation, which may help reduce muscle damage. It is classified pharmacologically as a p38 MAP kinase inhibitor.

Investigated diseases

Facioscapulohumeral Muscular Dystrophy 1 (FSHD1) – This is a genetic muscle disorder characterized by progressive muscle weakness and wasting. It primarily affects the muscles of the face, shoulders, and upper arms, leading to difficulties in facial expressions, lifting the arms, and other movements. The progression of muscle weakness can vary significantly among individuals, with some experiencing mild symptoms and others facing more severe challenges. Over time, the weakness may extend to other muscle groups, including those in the lower body. The onset of symptoms typically occurs in adolescence or early adulthood, but it can also appear later in life. The rate of progression and severity of symptoms can differ widely, even among members of the same family.
Trial detailsLast updated 2 Oct 2026
Age18+ yearsPhasePhase IITrial ID2024-512736-29-00Protocol codeFIS-001-2019Estimated enrolment14 patientsSponsorFulcrum Therapeutics Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

ClinicalTrials.eu

Every clinical trial in Europe, in plain language.

Explore the full ecosystem of clinical research in Europe.

Search trials

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).